Member of

Search for Daniel Joseph Beisang, Md, Phd, Pediatric Pulmonology, Duluth, MN.

Member of

The search results for your inquiry are provided below, along with Sources for further clarification.

Sources:

[1]

Aetnawww.aetna.com

[2]

Bluecrossmnwww.bluecrossmn.com

[3]

Bcbswww.bcbs.com

Overview

Practice

About

FAQ

Daniel Joseph Beisang, Md, Phd

Accepts new patients

Is this you? Manage your online reputation

Please wait while we find reviews for your provider...

Specialties

Pediatric Pulmonology

LocationDuluth, MN

Bio:

Dedicated to nurturing healthier lungs in children, this board-certifi...

Experience:

5+ years

Languages Spoken:

English

[20]

Common Treatments:

Asthma

Pneumonia

Influenza

See More

Institutes Attended:

UMN,

MBMP,

WMEB

Certificates:

MD,

PhD,

Fellow

[20]

See More

NPI/License number:

1649690355

Hospital Affiliations:

M Health Fairview Southdale Hospital

See More

AZ Awards:

Sex:

male

This is an AZ search result. This provider is not affiliated, endorsing or endorsed by AZcare, Please verify key information.

Sources:

[1]

Aetnawww.aetna.com

[2]

Bluecrossmnwww.bluecrossmn.com

[3]

Bcbswww.bcbs.com

Common Treatments:

Asthma

Pneumonia

Influenza

Chronic Bronchitis

Acute Bronchitis

Shortness of Breath

Respiratory Failure

Croup

Bronchitis

See More

Institutes Attended:

UMN,

MBMP,

WMEB

Certificates:

MD,

PhD,

Fellow

[20]

See More

NPI/License number:

1649690355

Hospital Affiliations:

M Health Fairview Southdale Hospital

See More

AZ Awards:

Sex:

male

Overview

Dr. Daniel Joseph Beisang is a highly skilled and dedicated pediatric pulmonologist committed to providing exceptional care for young patients with respiratory conditions. He is board-certified and fellowship-trained in Pediatric Pulmonology at the University of Minnesota Medical School. Dr. Beisang brings expertise in diagnosing and managing a wide spectrum of respiratory issues, including asthma, pneumonia, cystic fibrosis, bronchopulmonary dysplasia, and sleep apnea....

Practice

In-network insurance

[5][4]

Aetna

Alliant Health Plans

Anthem

Anthem Blue Cross Blue Shield

Blue Cross Blue Shield of Kansas City

Blue Cross Blue Shield of Minnesota

Insurance info is for reference only. Contact the provider to confirm they accept your plan, as some may decline certain insurances even if technically in-network.

Appointments Scheduling

[20]

Essentia Health St. Joseph's Baxter Clinic

Virtual Visit

Address:

13060 Isle Dr, Baxter, MN 56425

Phone:

(218) 786-3400

[20]

Essentia Health St. Mary's Superior Clinic

Virtual Visit

Address:

3500 Tower Ave, Superior, WI 54880

Phone:

(218) 786-3400

[21]

Essentia Health-Duluth Clinic 1st Street (Building A)

Virtual Visit

Address:

420 E 1st St, Duluth, MN 55805

Phone:

(218) 786-3400

Fax:

(701) 364-8476

About

NPI/License number:

1649690355

[18]

Experience:

5+ years

Languages Spoken:

English

[20]

Hospital Affiliations:

[20]

M Health Fairview Southdale Hospital

Essentia Health St. Mary's Hospital-superior

Essentia Health St. Mary's Medical Center

Essentia Health-st. Joseph's Medical Center

Specialties:

Pediatric Pulmonology

General Pediatric Pulmonology

Common Treatments:

Asthma

See More

Education & Certifications:

Doctor of Philosophy

University of Minnesota Medical School2017

Doctor of Medicine

University of Minnesota Medical School2014

Fellowship in Pediatric Pulmonology

University of Minnesota Medical School

Residency in Pediatrics

University of Minnesota Medical School

See More

Publications:

A CD44/Brg1 nuclear complex confers mesenchymal progenitor cells with enhanced fibrogenicity in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease driven by pathological changes in alveolar epithelium and fibroblast activation, yet current treatments only slow fibrosis without arresting it. Prior work identified a distinct population of fibrogenic mesenchymal progenitor cells (MPCs) in IPF lungs, characterized by a unique transcriptome and localized to the fibroblastic focus periphery. Single-cell RNA sequencing revealed that MPCs with high transcriptional network entropy also exhibit high CD44 expression (CD44^hi), suggesting enhanced fibrogenicity. This study confirmed that CD44^hi MPCs are concentrated at active fibrotic fronts and, using a humanized mouse xenograft model, demonstrated that CD44^hi IPF MPCs induce significantly greater fibrosis than CD44^lo MPCs despite similar engraftment levels. Knockdown of CD44 reduced fibrogenicity and self-renewal of these MPCs, indicating a mechanistic role for CD44 rather than it being a mere marker. Furthermore, CD44^hi MPCs exhibited increased pluripotency markers and self-renewal, potentiated by IL-8 signaling. Mechanistically, nuclear CD44 interacts with the chromatin remodeler Brg1 and transcription factor Zeb1 to upregulate Sox2, promoting fibrogenic self-renewal. These findings implicate CD44 and its epigenetic interactions as central drivers of cell-autonomous fibrosis progression in IPF.

By Libang Yang + 7 more

10-05-2021

Regulation of CUG-binding protein 1 (CUGBP1) binding to target transcripts upon T cell activation.

The RNA-binding protein CUGBP1 (also known as CELF1) regulates gene expression posttranscriptionally by binding GU-rich elements (GREs) in the 3′ untranslated regions (3′-UTRs) of target mRNAs, influencing their degradation, alternative splicing, and translation. This study investigated how CUGBP1 interacts with target transcripts in resting versus activated human primary T cells, employing RNA immunoprecipitation coupled with microarray analysis. Results demonstrated that resting T cells have numerous GRE-containing transcripts bound by CUGBP1, but upon T cell activation, CUGBP1 undergoes phosphorylation, which reduces its binding affinity for these GRE-containing mRNAs. This phosphorylation-driven decrease in binding leads to a substantial reduction in CUGBP1 target transcripts during activation. Many of these targets show rapid, transient changes in expression, with a significant portion being up-regulated, encoding regulatory proteins essential for T cell transition from quiescence to activation and proliferation. These findings reveal that CUGBP1 phosphorylation modulates a coordinated posttranscriptional regulatory network critical for T cell activation, altering mRNA stability and gene expression dynamics during immune responses.

By Daniel Beisang + 3 more

06-01-2012

Perspectives on the ARE as it turns 25 years old

The AU-rich element (ARE), first described in 1986 as a conserved AU-rich sequence in the 3′ untranslated regions (UTRs) of inflammatory mediator mRNAs like TNF-α, is a key posttranscriptional regulatory motif controlling mRNA stability and translation. AREs regulate approximately 5–8% of the transcriptome, particularly transcripts encoding cytokines, chemokines, and growth factors involved in inflammation, immune responses, and cellular proliferation. Their function is mediated by diverse ARE-binding proteins (e.g., HuR, TTP) that modulate mRNA decay, translation, and localization, often in a cell type- and activation-dependent manner. Recent research reveals interactions between ARE-mediated decay and microRNAs, adding layers of regulation, and highlights evolutionary conservation of ARE pathways from yeast to humans. Dysregulation of ARE-binding proteins, such as HuR upregulation or TTP downregulation, is implicated in oncogenesis by stabilizing transcripts promoting angiogenesis and proliferation, making them promising therapeutic targets. Advances in genome-wide technologies and bioinformatics are uncovering complex ARE-regulated transcript networks, driving future research towards therapeutic exploitation of ARE biology in diseases like cancer and autoimmunity.

By Daniel Beisang + 1 more

01-09-2012

Alternative Polyadenylation Regulates CELF1/CUGBP1 Target Transcripts Following T Cell Activation

This study used next-generation sequencing to analyze alternative polyadenylation (APA) changes in human T cells 6 and 24 hours after activation. They found that APA leads to transcript 3′ end shortening in a coordinated manner, especially affecting CELF1 (CUGBP1) target transcripts involved in cell proliferation. These transcripts typically contain GU-rich elements (GREs) in their 3′ untranslated regions (3′UTRs) that bind CELF1, promoting mRNA decay. The authors propose a model where, in resting T cells, CELF1 binds GREs located just downstream of proximal APA sites, blocking their usage and favoring distal polyadenylation sites. This results in longer transcripts containing GREs susceptible to degradation. Upon T cell activation, phosphorylation of CELF1 reduces its binding to GREs near proximal APA sites, allowing usage of these upstream sites, generating shorter transcripts that lack GREs and are thus stabilized, increasing expression. This mechanism links APA-mediated 3′UTR shortening with transcript stabilization and enhanced proliferation during T cell activation. These findings shed light on how APA coordinates post-transcriptional gene regulation of proliferation-related transcripts via CELF1, with broader implications for understanding proliferation in development, immune response, and cancer.

By Daniel Beisang + 2 more

15-10-2014

See More

Reviews

Aggregated Ratings: 4.7

Positive feedback

Neutral feedback

Negative feedback

FAQ

Dr. Beisang specializes in Pediatric Pulmonology and General Pediatric Pulmonology.

He treats asthma, pneumonia, cystic fibrosis, bronchopulmonary dysplasia, sleep apnea, interstitial lung disease, bronchitis, and respiratory failure.

He performs arterial blood gas tests, bronchoscopy (including robotic assist), and pulmonary rehabilitation services.

Yes, Dr. Beisang has experience in the assessment and management of cystic fibrosis and chronic lung diseases in children.

Yes, he diagnoses and treats pediatric sleep apnea and related breathing disorders.

He sees patients at Essentia Health St. Joseph's Baxter Clinic (13060 Isle Dr, Baxter, MN), Essentia Health St. Mary's Superior Clinic (3500 Tower Ave, Superior, WI), and Essentia Health-Duluth Clinic 1st Street (420 E 1st St, Duluth, MN).

Dr. Beisang earned his MD and PhD from University of Minnesota Medical School, completed his pediatrics residency and pediatric pulmonology fellowship at the same institution, and is board certified in Pediatric Pulmonology and Pediatrics.

He speaks English.

He accepts Aetna, Anthem, Blue Cross Blue Shield, Cigna, Curative, Delta Dental, First Health, Medicare, MultiPlan, Security Health Plan, UnitedHealthcare, and Medicaid.

Patients appreciate his clear explanations and caring approach, with an average rating of 4.7 out of 5 from 10 reviews.

Common Questions

What are the signs and symptoms of chronic obstructive pulmonary disease (COPD)?

Can a person with lung cancer still work?

What is the difference between asthma and COPD?

How can I reduce my risk of developing lung cancer?

What are the benefits of pulmonary rehabilitation?